- InterView
- Leclaza's ASCO data is like a global champion
- by An, Kyung-Jin May 28, 2021 06:08am
- The response rate for 'Lazertinib+Amivantamab' is the same as when ESMO was announced? It's ridiculous. The data is incomparably more complete than it was 7 months ago. " Professor Cho Byung-chul (oncology at Yonsei Cancer Hospital) commented on Leclaza (Lazertinib) combined data. A number of questions have been asked since the opening of
- InterView
- IQVIA provides a total solution based on big data
- by Eo, Yun-Ho May 20, 2021 05:41pm
- IQVIA(CRO Quintiles & IMS Healths) is much bigger than before. In addition to simply providing clinical referral and sales data, IQVIA includes development, release, and subsequent marketing and Rx management. IQVIA Korea, a so-called 'Human Data Science Company', recently acquired CoreZetta, a sample big data analysis company of the HIRA
- InterView
- "The reason why BI is the ‘Crown Jewel’ among all MNCs"
- by Eo, Yun-Ho May 10, 2021 06:22pm
- Multinational pharmaceutical companies are a dream job for many workers in the industry. With its high salary, good welfare, and smart business system, many multinational pharmaceutical companies have all the requirements that office workers desire. Even among these multinational pharmaceutical companies, Boehringer Ingelheim is considere
- InterView
- "Embrace precision medicine and tumor-agnostic therapy"
- by Eo, Yun-Ho Apr 30, 2021 06:12am
- “It’s our turn to adjust to tumor-agnostic therapies." HER2, ALK, EGFR, ROS1. These are keywords that frequently catch our eye in news about anticancer drugs. Times have changed. Effective treatment for patients these days depends on the genetic mutation of each patient. With treatments that target personalized genes continue being
- InterView
- KRPIA will introduce advanced new drugs and seek co-growth
- by Eo, Yun-Ho Apr 26, 2021 05:52am
- The Korean Research-based Pharmaceutical Industry Association (KRPIA), which represents the multinational pharmaceutical companies that are considered the key source for the supply of new drugs, welcomed a new leader last February. KRPIA’s newly appointed Chairman Dong-Wook Oh (51) has been leading Pfizer Pharmaceuticals Korea since 2
- InterView
- “Amgen knows how to do it right in Korea”
- by Eo, Yun-Ho Mar 25, 2021 05:59am
- Amgen knows the game in the industry. Besides the title of the ‘Number One Global Bio Company,’ Amgen Korea knows how to be versatile in South Korea. Since opening the South Korean office in 2015, Amgen listed all six products&8212;antiarthritis Prolia (denosumab) and Evenity (romosozumab), skeletal-related events preventing drug Xg
- InterView
- “High pressure and hopes in the policy affairs at KRPIA"
- by Eo, Yun-Ho Mar 11, 2021 06:07am
- Some say this is the era where policy comes first than an academy, and pricing is more important than an approval. The top priority for pharmaceutical companies in South Korea supplying new drug is the National Health Insurance (NHI) coverage. The era of highly expensive drug has emerged, while the government and pharmaceutical industry
- InterView
- There is still an unmet demand for antiviral drugs
- by Eo, Yun-Ho Mar 3, 2021 06:26am
- Currently, vaccines developed by AstraZeneca, Pfizer and others are a hot issue, but in the first half of last year, Remdesivir was ranked first as a keyword related to COVID-19. Gilead, the developer of Veklury (Remdesivir), is a pharmaceutical company specializing in antiviral drugs. It is leading and has pipelines in a variety of fields
- InterView
- Genexine Licenses out immuno-cancer Drug Technology
- by Kim, Jin-Gu Feb 22, 2021 06:17am
- Genexine announced on the 18th that it has signed a technology transfer contract worth &8361;1.2 trillion with KG BIO, a subsidiary of Indonesian pharmaceutical company Kalbe Farma, for GX-17, an immune anticancer drug candidate. KG BIO is a joint venture established in 2016 by Kalbe Farma, the largest pharmaceutical company in Southeast
- InterView
- Takeda's evolution continues
- by Eo, Yun-Ho Feb 16, 2021 06:08am
- It is difficult to stop what is going well. Even more so if it is a company's business. Takeda sold its diabetes and over-the-counter (OTC) business to Celltrion, a domestic company, last year. Takeda's Actos is a TZD-family drug that persisted in the Avandia outbreak, while Whituben and Albothyl are famous OTCs that everyone knows, mean
